Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianchang Lin

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Statistics in Medicine|June 12, 2019
Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpointsArup K Sinha, Lemuel Moye, Linda B Piller, et al.
Investigational New Drugs|May 24, 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participantsMichael J Hanley, Steven Zhang, Robert Griffin, et al.
International Journal of Cosmetic Science|October 26, 2023
Preparation and efficacy verification of three-dimensional printed partitioned multi-effect precision-care gel facial maskJunli Chen, Chunqiao Liufu, Wenfang Zhang, et al.
ACS Applied Bio Materials|December 2, 2025
An Anti-Inflammatory and Pro-Angiogenic Porous Aloe Polysaccharide-Collagen Dressing Accelerates Wound HealingQiong Jiang, MinShi Li, DanHong Chen, et al.
British Journal of Clinical Pharmacology|February 12, 2020
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjectsEric R Fedyk, Lin Zhao, Annelize Koch, et al.
JTO Clinical and Research Reports|September 25, 2023
Real-World Response and Outcomes in Patients With NSCLC With <i>EGFR</i> Exon 20 Insertion MutationsSai-Hong Ignatius Ou, Huamao M Lin, Jin-Liern Hong, et al.
Lung Cancer (Amsterdam, Netherlands)|April 19, 2023
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparisonSai-Hong I Ou, Huamao M Lin, Jin-Liern Hong, et al.
European Journal of Haematology|May 1, 2020
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activationAjeeta B Dash, Jacob Zhang, Lei Shen, et al.
Clinical Lung Cancer|December 19, 2023
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment ComparisonSai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|April 14, 2023
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutationsPetros Christopoulos, Thibaud Prawitz, Jin-Liern Hong, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Statistics in Medicine|June 12, 2019
Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpointsArup K Sinha, Lemuel Moye, Linda B Piller, et al.
Investigational New Drugs|May 24, 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participantsMichael J Hanley, Steven Zhang, Robert Griffin, et al.
International Journal of Cosmetic Science|October 26, 2023
Preparation and efficacy verification of three-dimensional printed partitioned multi-effect precision-care gel facial maskJunli Chen, Chunqiao Liufu, Wenfang Zhang, et al.
ACS Applied Bio Materials|December 2, 2025
An Anti-Inflammatory and Pro-Angiogenic Porous Aloe Polysaccharide-Collagen Dressing Accelerates Wound HealingQiong Jiang, MinShi Li, DanHong Chen, et al.
British Journal of Clinical Pharmacology|February 12, 2020
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjectsEric R Fedyk, Lin Zhao, Annelize Koch, et al.
JTO Clinical and Research Reports|September 25, 2023
Real-World Response and Outcomes in Patients With NSCLC With <i>EGFR</i> Exon 20 Insertion MutationsSai-Hong Ignatius Ou, Huamao M Lin, Jin-Liern Hong, et al.
Lung Cancer (Amsterdam, Netherlands)|April 19, 2023
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparisonSai-Hong I Ou, Huamao M Lin, Jin-Liern Hong, et al.
European Journal of Haematology|May 1, 2020
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activationAjeeta B Dash, Jacob Zhang, Lei Shen, et al.
Clinical Lung Cancer|December 19, 2023
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment ComparisonSai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|April 14, 2023
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutationsPetros Christopoulos, Thibaud Prawitz, Jin-Liern Hong, et al.
Pageof 8